MC Sciences is a pre-clinical stage company developing a new mast cell therapy platform with small molecules that target a wide range of diseases related to excessive mast cell activity and dysregulation of the mast cell function.
MC Sciences preferred objective is the comprehensive collaboration with a pharmaceutical company and / or life sciences venture capital companies to drive the further development of our new mast therapy platform and to bring it successfully to market and patients. This includes MCS1010 as potential candidate for drug repurposing for new disease indications.
Potentially, we are open to out-licensing MCS1010 for drug repurposing especially in disease indications with high unmet medical need in close cooperation with the intererts of potential cooperation partners and investors.
We look forward to your inquiries and engaging in a dialogue on investment and collaboration opportunities. In 2020, we plan investors conferences / meetings to demonstrate our new mast cell therapy platform.